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This study was conducted to retrospectively compare the clinical outcomes after transplantation of
T celledepleted (TCD) and unmodiﬁed allografts in patients with acute myeloid leukemia (AML) in ﬁrst
complete remission (CR1). Patients received TCD grafts at Memorial Sloan-Kettering Cancer Center
(MSKCC, N ¼ 115) between 2001 and 2010 using the following preparative regimens: hyperfractionated
total body irradiation (HFTBI)þthiotepaþﬂudarabine; HFTBIþthiotepaþcyclophosphamide; or i.v. busul-
fanþmelphalanþﬂudarabine. TCD was performed by 1 of 2 immunomagnetic CD34þ cell selection
methods for peripheral blood grafts or by soybean lectin agglutination followed by sheep red blood celle
rosette depletion for bone marrow grafts. No additional graft-versus-host disease (GVHD) prophylaxis was
administered. Patients received unmodiﬁed grafts at M.D. Anderson Cancer Center (MDACC, N ¼ 181) after
conditioning with busulfanþﬂudarabine and GVHD prophylaxis with tacrolimusþmini-methotrexate.
Patients with unrelated or human leukocyte antigenemismatched donors received anti-thymocyte glob-
ulin (ATG) at both centers, with some recipients of matched related donor TCD transplants also receiving
ATG, depending upon the preparative regimen. TCD graft recipients were more likely to be older, receive
a mismatched transplant, and have peripheral blood used as the graft source. The incidences rates of
grades 2 to 4 acute GVHD and chronic GVHD were signiﬁcantly lower in the TCD graft group (5% versus
18%, and 13% versus 53%). Three-year relapse-free and overall survival rates were 58% and 57%, respec-
tively, in recipients of TCD grafts, and 60% and 66% in recipients of unmodiﬁed grafts (P ¼ not signiﬁcant).
Survival and relapse-free survival are similar after TCD and conventional transplants from related/unre-
lated donors in patients with AML in CR1, but TCD signiﬁcantly reduces GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Despite the use of TCD grafts for over 3 decades, studies
A substantial number of patients with acute myeloid
leukemia (AML) relapse after achieving ﬁrst hematologic
complete remission (CR1) [1]. Allogeneic hematopoietic stem
cell transplantation (SCT) is a powerful tool to reduce the risk
of leukemia relapse. SCT is currently recommended for AML
patients in CR1 with poor-risk cytogenetics and should be
considered for those with intermediate risk [2,3]. However,
preparative regimen-related toxicities and graft-versus-host
disease (GVHD) associated with SCT have limited its wide-
spread use.
GVHD can be effectively prevented by ex vivo T cell
depletion of the donor graft without the morbidity associ-
ated with immunosuppressive drugs [4]. The early obser-
vation of immune-mediated graft rejection with the use of
T celledepleted (TCD) grafts was overcome with anti-
thymocyte globulin (ATG) at the expense of delayed
immune reconstitution [5].edgments on page 902.
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13.02.018comparing SCT with TCD versus SCT with unmodiﬁed
grafts are scarce. In a retrospective study including 146
patients with diverse hematological malignancies trans-
planted between 1997 and 1999, survival, GVHD rates, and
quality of life were found to be similar between patients
who received TCD and those who received unmodiﬁed
grafts [6]. In a multi-center, randomized phase 2/3 trial,
although acute GVHD incidence was found to be lower
after SCT with TCD grafts, there was no difference in
survival [7]. However, in both studies, T cell depletion was
accomplished by a physical method or by treatment of the
graft with antibodies achieving only 1 to 2 logs of deple-
tion compared with 3 to 5 logs of depletion that is ach-
ieved with the currently available magnetic selection
methods [8]. To compare the efﬁcacy of both approaches in
a more homogenous patient population and with current
day practices and technology, we retrospectively evaluated
the outcomes of patients with AML, who underwent
SCT with either TCD grafts at Memorial-Sloan Kettering
Cancer Center (MSKCC) or unmodiﬁed grafts at the
University of Texas M.D. Anderson Cancer Center (MDACC),
while in CR1.Transplantation.
Table 1
Comparison of Demographic and Clinical Characteristics of Patients Who
Underwent Transplantation with T CelleDepleted (TCD) or Unmodiﬁed
Grafts
Characteristics TCD N ¼ 115,
n (%)
Unmodiﬁed
N ¼ 181, n (%)
P Value
Age, yr* 52 (19-71) 48 (18-63) <.001
>50 66 (57) 76 (42) .010
Female 58 (50) 90 (50) NS
Time CR1 to transplantation, d* 83 (12-304) 97 (8-455) .040
Etiology <.001
de novo 60 (52) 144 (80)
Secondary 38 (33) 24 (13)
Therapy-related 17 (15) 13 (7)
Cytogenetic risk status NS
Good 1 (1) 2 (1)
Intermediate 72 (63) 103 (57)
Poor 42 (37) 76 (42)
Donor type <.001
Matched related 56 (49) 103 (57)
Matched unrelated 32 (28) 64 (35)
Mismatch 27 (23) 14 (8)
Donor/recipient gender NS
Match 54 (47) 89 (49)
Mismatch 61 (53) 92 (51)
Stem cell source <.001
Bone marrow 8 (7) 57 (32)
Peripheral blood 107 (93) 124 (68)
CR1 indicates ﬁrst complete remission; NS, not signiﬁcant.
* Data presented as median (range).
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After approval by MSKCC and MDACC respective institutional review
boards, AML patients older than 18 years, who underwent SCT between
2001 and 2010 with ablative preparative regimens while in CR1, were
identiﬁed through the institutional bone marrow transplantation (BMT)
registries. At MDACC, only those who received ﬂudarabine-busulfan
conditioning were included in the study to preserve the homogeneity of
the cohort. At MSKCC, all consecutively transplanted patients with AML CR1
over this time period were included in the analysis. Demographics, disease
characteristics, treatment, GVHD, and survival data were retrieved from
departmental databases at the respective institutions. Complete remission
was deﬁned as 5% blasts in bone marrow, absence of blasts in peripheral
blood, platelet count 100 K/mL, and absolute neutrophil count 1000/mL.
Cytogenetic risk stratiﬁcation considered complex cytogenetics, -5, -5q, -7,
-7q, 11q23 aberrations, inv(3), t(3;3), t(6;9), t(9;22) as poor risk; and t(8;21),
t(16;16), inv(16), t(15;17) as good risk [9]. Donorerecipient human leuko-
cyte antigen (HLA) matching was established by DNA sequence-speciﬁc
oligonucleotide typing for HLA-A, -B, -Cw, -DQB1, and -DRB1 loci, in both
institutions.
Patients at MSKCC received TCD grafts (TCD graft group, N ¼ 115) after
conditioning with 1 of the following preparative regimens as previously
reported [10-12]: (1) hyperfractionated total body irradiation (HFTBI) 1375
centigray (cGy) over 4 days followed by thiotepa 5 mg/kg/day i.v. for 2 days
and ﬂudarabine 25 mg/m2/day i.v. for 5 days beginning on the ﬁrst day of
thiotepa (n ¼ 29); (2) HFTBI 1375 cGy over 4 days followed by thiotepa
5 mg/kg/day and cyclophosphamide 60 mg/kg/day i.v. for 2 days (n¼ 25); or
(3) busulfan .8 mg/kg i.v. every 6 hours for 10 doses (n¼ 42) or 12 doses (n¼
19), with doses of busulfan adjusted according to pharmacokinetics,
melphalan 70 mg/m2/day i.v. for 2 days, and ﬂudarabine 25 mg/m2/day
i.v. for 5 days (total n ¼ 61). Six patients in the HFTBIþthiote-
paþcyclophosphamide group were also enrolled on BMT CTN 0303 [13].
Patients >60 years of age and those patients with therapy related or
secondary AML received the regimen without total body irradiation.
Peripheral blood grafts underwent CD34þ cell selection using the ISOLEX
300i magnetic cell selection system (Baxter, Deerﬁeld, IL), followed by sheep
red blood cellerosette depletion (n ¼ 85); or CD34þ cell selection using the
CliniMACS cell selection system (Miltenyi Biotech, Gladbach, Germany)
alone (n ¼ 22). Bone marrow (BM) grafts were used upon donor preference
and were depleted of T cells by sequential soybean lectin agglutination and
sheep red blood cellerosette depletion (n ¼ 8). All patients received equine
(total 60 mg/kg) or rabbit (2.5 mg/kg to 5 mg/kg) ATG to prevent graft
rejection, except for those patients receiving a transplant from an HLA-
matched related donor and conditioned with HFTBIþthiotepaþﬂudarabine
[10]. No GVHD prophylaxis was administered post-transplantation.
Patients at MDACC received unmodiﬁed grafts (unmodiﬁed graft group,
N ¼ 181) after an ablative, reduced-toxicity preparative regimen consisting
of ﬂudarabine 40 mg/m2/day over 1 hour and busulfan 130 mg/m2/day i.v.
over 3 hours for 4 days (days -6 to -3) [14]. Patients with unrelated or
HLA-mismatched donors received equine (total 60 mg/kg) or rabbit (total
2.5 mg/kg to 5 mg/kg) ATG. Tacrolimus and mini-methotrexate (5 mg i.v. on
days 1, 3, 6, and 11) were used for GVHD prophylaxis. Fifteen patients also
received pentostatin under an investigational protocol on days 8, 15, 22, and
30 at 1 mg/m2 or 1.5 mg/m2.
Patients were managed clinically according to MSKCC and MDACC
standard guidelines including infection prophylaxis for Pneumocystis carinii,
herpes viruses, and fungus. Patients received no cytomegalovirus (CMV)-
speciﬁc prophylaxis and were regularly monitored for CMV reactivation by
CMV pp65 antigenemia assay of peripheral blood in both institutions.
Preemptive therapy was instituted in patients with documented CMV
viremia. Patients in the TCD cohort were also monitored regularly for
Epstein-Barr virus reactivation in the peripheral blood by polymerase chain
reaction, per institutional guidelines. Patients received granulocyte colony-
stimulating factor beginning at day þ7 after transplantation.
GVHD was diagnosed clinically, conﬁrmed pathologically whenever
possible, and classiﬁed according to standard criteria [15]. GVHD diagnosed
after day 100 post-transplantation was classiﬁed as chronic GVHD. Only
patients who engrafted were evaluable for GVHD assessment. Data were
updated as of July 2011.
Patients’ characteristics were compared between the TCD and unmod-
iﬁed graft groups using the chi-square test and Wilcoxon’s rank sum test.
Overall survival (OS) and relapse-free survival (RFS) were deﬁned as the
time from SCT until death from any cause, and disease relapse or death,
respectively. Non relapse mortality (NRM) was deﬁned as death in a patient
without leukemia relapse. Univariate probabilities of OS and RFS were
estimated using the Kaplan-Meier method with 95% conﬁdence intervals
(95% CI) calculated using log transformed intervals. Predictors of OS and RFS
by 3 years post-transplantationwere assessed in univariate andmultivariate
analyses using Cox’s proportional hazards regression analysis. The pro-
portionality of the hazards assumptionwas tested on the basis of Schoenfeldresiduals and was found to be met when assessed overall and by 3 years
post-transplantation.
Predictors considered included type of graft (TCD versus unmodiﬁed),
age (older than 50 years), donor/recipient gender (female to male versus all
other), leukemia etiology (primary, secondary, therapy-related), cytogenetic
risk group, donor type (HLA-matched related versus HLA-matched unre-
lated, or HLA-mismatched), and stem cell source (bone marrow versus
peripheral blood). Predictors signiﬁcant on univariate analysis were evalu-
ated in multivariate analysis. Potential interaction effects by graft type were
assessed by stratiﬁed analysis, and were tested statistically using ﬁrst-
degree interaction-effect terms in Cox’s regression analysis. When indi-
cated, interaction effects were adjusted for in multivariate analysis. The
cumulative incidence of NRM, leukemia relapse, and GVHD was estimated
based on the cumulative incidence method to account for competing risks.
Leukemia relapse, death in the absence of leukemia relapse, and relapse or
death in the absence of GVHD were considered competing risks for NRM,
leukemia relapse, and GVHD, respectively.
Cox’s regression analysis was used to compare the rate of NRM, disease
relapse, and GVHD according to graft type in univariate analysis. Statistical
signiﬁcance was determined at the .05 level. Statistical analysis was per-
formed using STATA 11.0.
RESULTS
Patient demographic and clinical characteristics are
summarized in Table 1. TCD graft recipients were signiﬁ-
cantly older, less likely to have de novo AML, and more likely
to have HLA-mismatched donors. Peripheral blood was
almost exclusively the graft source used in the TCD graft
group. Time from achievement of CR1 to transplantationwas
longer in patients who received unmodiﬁed grafts.
Overall Survival and Relapse-Free Survival
As of July 2011, the median (range) follow-up among
surviving patients was 32 months (.5 to 108 months) and
29 months (2 to 104 months) for the TCD and unmodiﬁed
graft groups, respectively. Accordingly, outcomes in the TCD
and unmodiﬁed groups were compared within 3 years post-
transplantation. A total of 43 deaths (37%) and 18 relapses
(16%) occurred in the TCD graft group, and a total of 54
deaths (30%) and 42 relapses (23%) occurred in the
Table 3
Predictors of Overall Survival (OS) and Relapse-free Survival (RFS) Evaluated
by Univariate Analyses
Value RFS, HR at 3
years (95% CI)
OS, HR at 3
years (95% CI)
Age, yr
50 Reference
>50 1.0 (.7-1.4) 1.1 (.8-1.7)
Gender
Male Reference
Female 1.1 (.7-1.7) 1.1 (.7-1.5)
Etiology
de novo Reference
Secondary 1.4 (.9-2.2) 1.7 (1.1-2.8)*
Therapy-related .9 (.4-1.7) .9 (.4-2.0)
Cytogenetic risk
Good/intermediate Reference
Poor 1.1 (.7-1.6) .9 (.6-1.4)
Donor type
Matched related Reference
Matched unrelated 1.1 (.8-1.7) 1.2 (.8-1.9)
Mismatch 1.0 (.5-1.7) 1.2 (.7-2.2)
Stem cell source
Bone marrow Reference
Peripheral blood 1.4 (.8-2.5) 1.6 (.9-2.9)
Graft type
T celledepleted Reference
Unmodiﬁed .9 (.6-1.4) .7 (.5-1.1)
* P ¼ .02.
Table 2
Comparison of Outcomes in the T CelleDepleted (TCD) and Unmodiﬁed
Graft Groups Based on Univariate Analysis Using Cox’s Proportional Hazards
Regression
Outcome TCD
(95% CI)
Unmodiﬁed
(95% CI)
P Value
Relapse-free survival
1 yr 62% (51-70) 65% (57-72) .6
3 yr 58% (47-67) 60% (51-67) .7
Overall survival
1 yr 68% (58-76) 74% (66-80) .3
3 yr 57% (47-67) 66% (58-74) .2
Relapse incidence
1 yr 17% (11-26) 21% (15-28) .4
3 yr 18% (12-27) 25% (19-33) .3
Nonrelapse mortality
100 d 8% (4-15) 3% (1-7) .07
1 yr 18% (12-27) 13% (9-19) .2
3 yr 24% (17-34) 16% (11-23) .1
Acute GVHD (grade 2-4)
100 d 5% (2-11) 18% (13-24) .005
Chronic GVHD
3 yr 13% (8-22) 53% (46-62) <.001
GVHD indicates graft-versus-host disease.
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ison of outcomes within 3 years (Table 2) showed no
signiﬁcant differences between TCD and unmodiﬁed graft
recipients in regard to OS (57% versus 66%, P ¼ .2, Figure 1),
RFS (58% versus 60%, P ¼ .7), or rate of relapse (18% versus
25%, P ¼ .3).Figure 1. Probabilities of overall (top) and relapse-free (bottom) survival
among recipients of T celledepleted (TCD) and unmodiﬁed grafts.Nonrelapse Mortality
The cumulative incidence of NRM at day 100, 1 year, and
3 yearswere 8%,18%, and24% in theTCDgraft group compared
with3%,13%, and16% in theunmodiﬁedgraft group. Therewas
no signiﬁcant difference in the rate of NRM between the TCD
and unmodiﬁed groups (P ¼ .1). Causes of death in the TCD
graft group included relapsed leukemia (n¼17, 40%), infection
(n¼ 11, 26%), GVHD (n¼ 5, 12%), organ toxicities (n¼ 5, 12%),
graft failure (n ¼ 2, 4%), solid malignancies (n ¼ 2, 4%), and
post-transplantation lymphoproliferative disease (n ¼ 1, 2%).
In the unmodiﬁed graft group, causes of death included
relapsed disease (n ¼ 27, 50%), infection (n ¼ 6, 11%), GVHD
(n¼12, 22%), organ toxicities (n¼3, 6%), graft rejection/failure
(n ¼ 4, 7%), and solid malignancies (n ¼ 1, 2%). Overall, there
was no signiﬁcant difference in the distribution of the causes
of death between the TCDandunmodiﬁed groups.Within 100
days post-transplantation, 6 (5%) and 2 (1%) patients died of
infections in the TCD and unmodiﬁed groups (P ¼ .04),
respectively.
Graft-versus-Host Disease
The rate of grade 2 to 4 acute GVHD occurring within
100 days post-transplantation was signiﬁcantly lower in the
TCD graft group compared with the unmodiﬁed graft group
(5% versus 18%, P ¼ .005). There was no signiﬁcant difference
in the rate of grade 3 to 4 acute GVHD between the 2 groups
(1% versus 3%, P¼ .3). Within 3 years post-transplantation,14
and 78 patients developed chronic GVHD, of which 5 and 55
were extensive, in the TCD and unmodiﬁed graft groups,
respectively. The rate of chronic GVHD was lower in the TCD
graft group (13% versus 53%, P < .001).
Prognostic Factors
None of the prognostic factors evaluated (listed in
methods section), including the type of graft, were signiﬁ-
cantly associated with OS or RFS, except for etiology of AML
(Table 3). Compared with primary AML, secondary AML
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[HR] ¼ 1.7, P ¼ .02), but did not impact RFS (HR ¼ 1.4, P ¼ .1).
To determine if the factors evaluated had the same impact in
the TCD and unmodiﬁed groups, we performed a stratiﬁed
analysis evaluating the association between the prognostic
factors and outcomes separately in these 2 groups. This
stratiﬁed analysis showed that the impact of recipient gender
on OS and RFS differed according to the type of graft. Female
gender was associated with signiﬁcantly lower OS (HR ¼ 2.2,
P ¼ .01) and RFS (HR ¼ 2.3, P ¼ .01) in the TCD group, but not
in the unmodiﬁed group (HR ¼ .7, P ¼ .2; HR ¼ .6, P ¼ .07).
This association was independent of the donor’s gender. All
other factors considered had the comparable impact on OS
and RFS in the TCD and unmodiﬁed groups.
Onmultivariate analysis, secondary AMLwas signiﬁcantly
associated with lower OS (HR ¼ 1.7, P ¼ .02), and female
gender in the TCD group was signiﬁcantly associated with
lower OS (HR ¼ 1.9, P ¼ .004) and RFS (HR ¼ 1.7, P ¼ .01).
There was no independent effect for graft type on OS or RFS
in multivariate analysis.Subset Analysis
Because the distribution of age >60 years, HLA compati-
bility, and AML etiology differed signiﬁcantly between the
TCD and unmodiﬁed groups, we compared outcomes by graft
type in a relatively homogeneous group that included
patients <60 years of age who received a graft from a 10/10
HLA compatible donor, and who did not have secondary
AML. Results of this subset analysis were comparable with
those obtained overall, showing no signiﬁcant difference in
OS (HR ¼ .6, P ¼ .1) or RFS (HR ¼ .8, P ¼ .4) in the TCD group
(n ¼ 42) compared with the unmodiﬁed group (n ¼ 135).
Comparable results were obtained when analysis was
restricted to younger patients with primary AML and 10/10
compatible donors.DISCUSSION
Ex vivo T cell depletion of the graft is the most effective
method to prevent GVHD after SCT. However, approaches to T
cell depletion have varied greatly in the levels of T cell deple-
tion achieved, and most have also incorporated post-trans-
plantation immunosuppression.Asa consequence, the roleof T
cell depletion alone in transplantation for hematologic malig-
nancies has not been well established and only a minority of
centers in the United States use this procedure. However,
signiﬁcant changes have also occurred in T cell depletion
technology with CD34þ selection, including methods that
provide a 1-2 log10 greater T cell depletion replacing mono-
clonal or polyclonal antibodies directed against T cell epitopes
[8,16]. Signiﬁcant changes have also been made to traditional
conditioning regimens primarily substituting ﬂudarabine for
cyclophosphamide and the introduction of intravenous
busulfan [14,17,18]. Furthermore, advances in molecular
diagnostic and supportive care have greatly reduced
transplantation-related mortality due to viral infections.
To compare the outcomes of TCD grafts using positive
CD34 selection technology to calcineurin inhibitorebased
GVHD prophylaxis when used with more tolerable condi-
tioning regimens employing ﬂudarabine and/or busulfan, we
analyzed the clinical outcomes of 115 and 181 patients with
AML who were transplanted while in CR1 with TCD and
unmodiﬁed grafts at MSKCC and MDACC, respectively.
Survival rates were similar, albeit with signiﬁcantly lower
incidence of acute and chronic GVHD in those who receivedTCD grafts. None of the TCD grafts were rejected with the use
of ATG and ablative conditioning.
Though T cell depletion has been associated with
a higher risk of relapse in patients with chronic myeloid
leukemia [19-22], this has not been the case for patients
with acute leukemia. Soiffer and colleagues [23] reported
their results using amonoclonal antibody for T cell depletion
in patients with AML undergoing transplantation in ﬁrst CR.
The majority of these patients had adverse clinical features
or poor-risk cytogenetics. The 4-year estimated incidence
rates of relapse and event-free survival were 25% and 63%,
respectively. Similarly, Wagner et al. [7] reported on results
of a prospective randomized trial comparing T cell depletion
to unmodiﬁed transplants in patients with hematologic
malignancies undergoing unrelated donor transplantations.
In this report, there was no statistical difference between
the 2 cohorts with respect to the incidence of relapse for
patients with AML, though there was a statistically lower
incidence of grade 2 through 4 GVHD. Our own results again
did not demonstrate an increased risk of relapse in the
recipients of TCD grafts. However, the more intense
preparative regimen used in the TCD group may have offset
any reduction in graft-versus-leukemia effect.
More recently, in the prospective Blood and Marrow
Transplantation Clinical Trials Network (BMT-CTN) 0303 trial
of TCD transplants in AML [13], the relapse incidence was
reported as 17% at 3 years among those in CR1, similar to
those reported in prospective trials of T cell replete trans-
plants [24-26]. Furthermore, Pasquini et al. compared the
outcomes of patients treated on the BMT-CTN 0303 TCD trial
to similar patients who received unmodiﬁed grafts between
2003 and 2006 on BMT-CTN 0101 protocol. No signiﬁcant
differences in relapse incidence, NRM, or survival were
observed between the 2 patient groups [27].
In our study cohort, both acute and chronic GVHD rates
were lower in the recipients of TCD grafts comparedwith the
recipients of unmodiﬁed grafts, despite the higher preva-
lence of mismatched donors in the former group. Ex vivo T
cell depletion of the donor graft has been consistently
associated with reduced GVHD and is considered the most
effective method for prevention of GVHD [7,28,29]. However,
the degree of T cell depletion and methods used may inﬂu-
ence the incidence of GVHD [4,28,30-32]. With 1 to 2 logs of
T cell depletion, Lee et al. reported no difference in GVHD
rates between TCD and T cell replete transplants from
unrelated donors. With the T cell depletion techniques
utilized by the MSKCC group, 3 to 4 logs of T cell depletion
were achieved resulting in the signiﬁcantly lower incidence
of both acute and chronic GVHD seen in this group.
In our cohort, ex vivo T cell depletion was not associated
with improved OS or RFS rates when compared with those
for recipients of unmodiﬁed grafts, despite having lower
rates of acute and chronic GVHD and similar relapse risk. OS
in both groups were comparable to that previously reported
in AML patients in CR1 [26,33]. Likewise, previous reports
comparing TCD with unmodiﬁed grafts did not demonstrate
any difference in survival [6,7], suggesting that advances in
SCT affected both methods equally. Though there was a trend
toward a higher NRM at day 100 in the TCD cohort, there
were no differences between the 2 groups in 1-year and
3-year NRM. The early NRM in the TCD cohort was attributed
to infectious deaths, most of which were in the early peri-
transplantation period and bacterial in nature. Therefore,
they could not be attributed to delayed quantitative and
functional recovery of T cells [5,34-37]. However, the
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compared with the MDACC busulfan and ﬂudarabine
regimen could potentially explain the trend toward a higher
early NRM in the TCD group.
Relapse was the most important cause of treatment
failure in both groups, and strategies aimed at preventing
post-transplantation relapse will be essential to improve
transplantation outcomes regardless of graft source. Moving
forward, the ability to deliver post-transplantation therapies
will need to be carefully assessed when comparing TCD with
other GVHD-prevention strategies.
Our study has several limitations, with the retrospective
nature of data collection being the foremost. This has led to
signiﬁcantly different patient/donor characteristics between
the 2 groups. Second, some of the patients were treated
under investigational trials that may have led to selection
bias. Moreover, comparing transplant procedures between
the 2 different centers may have introduced confounding
variables for which we may have not accounted (ie, patient
selection and differences in supportive therapy).
It appears from this retrospective study that survival is
similar between patients receiving TCD transplants and
those receiving conventional transplants, with a reduced
GVHD rate after the former. Our results support the need
for a randomized prospective trial comparing TCD with
unmodiﬁed grafts in homogeneous populations.ACKNOWLEDGMENTS
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